Diagnostic Pathology · 2012 · 18 citations · 23 references
MedicineOncologyPathologyGenitourinary OncologyMolecular OncologyUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerGenitourinary Cancer SurgeryUrologic Cancer DiagnosisUrothelial CarcinomaBladder Cancer Recurrence BiomarkersCyclooxygenase-2 PathwayImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingRecurrenceTissue Microarrays
BACKGROUND: A new modality is necessary to prevent recurrence of superficial bladder cancer after complete transurethral resection because of the high recurrence rate even with current prophylaxis protocols. METHODS: In order to analyze the predictive value of cyclooxygenase-2 (COX-2) expression and tumor infiltrating lymphocytes (TILs) in recurrence of this disease tumor specimens from 127 patients with solitary papillary non-muscle invasive bladder cancer (NMIBC), 78 with recurrent disease and 49 without recurrence during follow up of minimum 5 years, were retrieved for tissue microarrays construction and immunohistochemical analysis. COX-2 expression was scored according to Allred's scoring protocol, while presence of TILs was categorized as absent (no) or present (yes) on whole tissue sections. RESULTS: COX-2 immunoreactivity was presented in 70 (71%), weak in 16% and strong in 55% of cases, while 29 (29%) tumors were negative. TILs were present in 64 (58%) NMIBC, while 44 cases (41%) did not reveal mononuclear infiltration in tumoral stroma. Statistical analysis demonstrated a higher proportion of patients with recurrence in the group with the COX-2 score 0, and lower in the group with score 2 (p=0.0001, p=0.0101, respectively). In addition, a higher proportion of recurrent patients in the group with no TILs, and lower proportion in the group with TILs were found (p=0.009, p=0.009, respectively). Univariate and multivariate analysis revealed overexpression of COX-2 and presence of TILs as negative predictors. CONCLUSION: Patients with lower COX-2 expression and absence of TILs in NMIBC need to be followed up more vigorously and probably selected for adjuvant therapy. VIRTUAL SLIDE: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1411318819790406.
23
Rebecca L. Siegel, Elizabeth Ward, Otis W. Brawley et al. · CA A Cancer Journal for Clinicians · 2011 · 4.1K citations · Full text
Richard Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck et al. · European Urology · 2006 · 3K citations
AJCC Cancer Staging Manual. 6th ed
FL Greene, DL Page, Fleming Id et al. · 2002 · 2.3K citations
AJCC Cancer Staging Manual, 6th edition
Hans‐Joachim Schmoll · Annals of Oncology · 2003 · 736 citations · Full text